Isolated vitamin D supplementation improves the adipokine profile of postmenopausal women: a randomized clinical trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The aim of the study is to evaluate the effect of vitamin D supplementation alone on the adipokine profile of postmenopausal women.

Who Took Part

The study group was 160 women.

PubMed tags the participants as women only.

Women with amenorrhea 12 months or more and aged 50 to 65 years were included.

Women with established cardiovascular disease, insulin-dependent diabetes, renal failure, liver diseases, and previous use of menopausal hormone therapy and vitamin D were excluded.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

The intervention lasted 9 months and serum adiponectin, resistin, and adipsin levels were determined at the start and end of treatment.

Intention to treat was adopted as the statistical method using a repeated measures design, followed by Wald's multiple comparison test adjusted for group × time interaction.

What Was Measured

The subject headings attached to it are Resistin, Complement Factor D, Adipokines, Adiponectin, Postmenopause, Dietary Supplements and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 160 women.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Menopause (New York, N.Y.)), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.